Prevalence of Past and Reactivated Viral Infections and Efficacy of Cyclosporine A As Monotherapy or in Combination in Patients with Psoriatic Arthritis--synergy Study: a Longitudinal Observational Study

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2014 May 8

PMID 24804261

Citations 11

Authors

Delia Colombo

Sergio Chimenti

Paolo Grossi

Antonio Marchesoni

Sergio Di Nuzzo

Vito Griseta

Anna Gargiulo

Aurora Parodi

Lucia Simoni

Gilberto Bellia

Affiliations

Soon will be listed here.

Abstract

We have prospectively evaluated psoriatic arthritis (PsA) patients for (1) seropositivity for former viral infections and seroconversion and (2) efficacy of cyclosporine A (CsA) alone or in combination with other immunosuppressants in a time period of 12 months. Screening included HBV antibodies and antigens, HCV antibodies and RNA, HSV 1-2, HZV, EBV, and CMV IgG, and IgM, HHV-6 DNA, and HIV 1-2 antibodies. PsA was evaluated by the Psoriasis Area Severity Index (PASI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and the Visual Analogue Scale (VAS). At baseline, 126 (56%) out of 225 evaluable patients had 2 or more seropositivities indicative of former infections, and 31 patients (13.8%) presented seropositivity for HCV, HBV, HSV-1 and -2, HHV-6, EBV, or parvovirus infection; one of them, positive for HBAg, was treated with lamivudine, while the remaining 30 received no specific treatment. None of the 31 patients developed virus reactivation. A reduction (P < 0.001) of PASI, BASDAI, and VAS scores was observed at 6 and 12 months. The treatment of PsA with CsA as monotherapy or in combination was safe and effective. In vitro experiments and clinical findings, including those from our study, suggest that CsA as monotherapy or in combination with biologics might be the treatment of choice in PsA HCV-positive patients.

Citing Articles

The Impact of Immune-Modulating Treatments for Dermatological Diseases on the Risk of Infection with SARS-CoV-2 and Outcomes Associated with COVID-19 Illness.

Maynard N, Armstrong A Curr Dermatol Rep. 2023; 12(2):45-55.

PMID: 37304177 PMC: 10068706. DOI: 10.1007/s13671-023-00385-w.

Use of Cyclosporine Therapy in Dermatology During COVID-19 Pandemic.

Pathania Y Actas Dermosifiliogr. 2022; 113(7):657-658.

PMID: 35132273 PMC: 8809675. DOI: 10.1016/j.ad.2021.10.009.

Cyclosporin A: A Repurposable Drug in the Treatment of COVID-19?.

Devaux C, Melenotte C, Piercecchi-Marti M, Delteil C, Raoult D Front Med (Lausanne). 2021; 8:663708.

PMID: 34552938 PMC: 8450353. DOI: 10.3389/fmed.2021.663708.

Which immunosuppressive drug is preferred in the treatment of toxic epidermal necrolysis during COVID-19 outbreak?.

Farajzadeh S, Ahramiyanpour N Clin Case Rep. 2021; 9(5):e04249.

PMID: 34026201 PMC: 8123742. DOI: 10.1002/ccr3.4249.

Infectious Complications in Autoimmune Hemolytic Anemia.

Giannotta J, Fattizzo B, Cavallaro F, Barcellini W J Clin Med. 2021; 10(1).

PMID: 33466516 PMC: 7796467. DOI: 10.3390/jcm10010164.

References

Garrett S, Jenkinson T, Kennedy L, Whitelock H, Gaisford P, Calin A . A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994; 21(12):2286-91. View

Nakagawa M, Sakamoto N, Tanabe Y, Koyama T, Itsui Y, Takeda Y . Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology. 2005; 129(3):1031-41. DOI: 10.1053/j.gastro.2005.06.031. View

Yang F, Robotham J, Nelson H, Irsigler A, Kenworthy R, Tang H . Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J Virol. 2008; 82(11):5269-78. PMC: 2395199. DOI: 10.1128/JVI.02614-07. View

Galeazzi M, Bellisai F, Giannitti C, Manganelli S, Morozzi G, Sebastiani G . Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection. Ann N Y Acad Sci. 2007; 1110:544-9. DOI: 10.1196/annals.1423.058. View

Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K . Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology. 2003; 38(5):1282-8. DOI: 10.1053/jhep.2003.50449. View

FREDRIKSSON T, Pettersson U . Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978; 157(4):238-44. DOI: 10.1159/000250839. View

Hawker G, Mian S, Kendzerska T, French M . Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain.... Arthritis Care Res (Hoboken). 2012; 63 Suppl 11:S240-52. DOI: 10.1002/acr.20543. View

Giannitti C, Benucci M, Caporali R, Manganelli S, Bellisai F, Sebastiani G . Efficacy and safety of anti-TNF-alpha therapy combined with cyclosporine A in patients with rheumatoid arthritis and concomitant hepatitis C virus infection. Int J Immunopathol Pharmacol. 2009; 22(2):543-6. DOI: 10.1177/039463200902200233. View

Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H . Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006; 54(8):2665-73. DOI: 10.1002/art.21972. View

10.

Ciesek S, Steinmann E, Iken M, Ott M, Helfritz F, Wappler I . Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology. 2010; 138(5):1875-84. DOI: 10.1053/j.gastro.2010.02.004. View

11.

Gossec L, Smolen J, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D . European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2011; 71(1):4-12. DOI: 10.1136/annrheumdis-2011-200350. View

12.

Salaffi F, De Angelis R, Grassi W . Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. Clin Exp Rheumatol. 2006; 23(6):819-28. View

13.

Levy G, Grazi G, SanJuan F, Wu Y, Muhlbacher F, Samuel D . 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl. 2006; 12(10):1464-72. DOI: 10.1002/lt.20802. View

14.

Giannitti C, Fineschi I, Frediani B, Fioravanti A, Galeazzi M . Efficacy and safety of tocilizumab combined with cyclosporine A in a patient with rheumatoid arthritis and concomitant chronic hepatitis C virus infection. Clin Exp Rheumatol. 2013; 31(5):816. View

15.

Ciesek S, Wedemeyer H . Immunosuppression, liver injury and post-transplant HCV recurrence. J Viral Hepat. 2011; 19(1):1-8. DOI: 10.1111/j.1365-2893.2011.01548.x. View

16.

Love T, Zhu Y, Zhang Y, Wall-Burns L, Ogdie A, Gelfand J . Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis. 2012; 71(8):1273-7. PMC: 3645859. DOI: 10.1136/annrheumdis-2012-201299. View

17.

Vassilopoulos D, Calabrese L . Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections. Curr Opin Rheumatol. 2007; 19(6):619-25. DOI: 10.1097/BOR.0b013e3282f05b63. View

18.

Miura H, Itoh Y, Matsumoto Y, Tani M, Tanabe N, Isonokami M . Long-term administration of cyclosporin A to HCV-antibody-positive patients with dermatologic diseases. Int J Dermatol. 1999; 38(4):310-4. DOI: 10.1046/j.1365-4362.1999.00690.x. View

19.

Levy G, Villamil F, Samuel D, SanJuan F, Grazi G, Wu Y . Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation. 2004; 77(11):1632-8. DOI: 10.1097/01.tp.0000129095.51031.42. View

20.

Chandran V . Epidemiology of psoriatic arthritis. J Rheumatol. 2009; 36(2):213-5. DOI: 10.3899/jrheum.081242. View